In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mannatech earnings

This article was originally published in The Tan Sheet

Executive Summary

Coppell, Texas-based supplement firm's sales increased 56.1% to $77.6 mil. with earnings up 136% to $6.8 mil. in the third quarter, Mannatech announces Nov. 9. The results mark the firm's eighth consecutive quarter of growth, and include its September entry into the South Korean market and signing of a deal with Australian biotech firm Marinova to make microalgae-derived biotherapeutics (1"The Tan Sheet" Sept. 13, 2004, In Brief)...

You may also be interested in...



Mannatech deal

Coppell, Tex.-based firm enters into exclusive multi-year supply agreement with Marinova, an Australian biotech firm specializing in biotherapeutics derived from the macro algae Undaria pinnatifida (brown seaweed), Mannatech announces. The contract is "part of an ongoing effort to secure the best and most exclusive worldwide sources of natural, plant-synthesized polysaccharide structures," CEO Sam Caster says. Marinova has developed a method of using a sulphate polysaccharide galactofucan sulphate and created "a patent-pending high-molecular weight fucoidan product," according to a release...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS097518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel